Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy.
Adipokine
Asprosin
Diabetic nephropathy
Insulin resistance
Type 2 diabetes
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
25
04
2021
accepted:
08
07
2021
pubmed:
26
7
2021
medline:
28
10
2021
entrez:
25
7
2021
Statut:
ppublish
Résumé
Adipokines play an important role in the development of type 2 diabetes mellitus (T2DM) and its complications like nephropathy. Asprosin is a newly discovered adipokine involved in glucose metabolism and inflammation process. The present study aimed to evaluate asprosin levels in patients with T2DM and T2DM + nephropathy (NP) compared to control subjects as well as investigating its relationship with insulin resistance, inflammation, and renal function markers. Serum levels of asprosin, adiponectin, IL-6, and TNF-α were measured in 55 control subjects, 54 T2DM, and 55 T2DM + NP patients using ELISA kits. Asprosin was found to be higher in the T2DM (6.73 ± 1.67) and T2DM + NP (7.11 ± 1.54) patients compared to the controls (4.81 ± 1.09) (p < 0.001), while adiponectin indicated a lower concentration in both patient groups compared to the control group. Moreover, IL-6 and TNF-α indicated higher levels in the two patients group compared to the control group. Asprosin was observed to have a positive correlation with HbA1c, FBG, TC, LDL-C, IL-6, and TNF-α in the T2DM group. In the patients with T2DM + NP, asprosin was found to be positively correlated with BMI, HbA1c, insulin, HOMA-IR, Cr, UAE, IL-6, and TNF-α, and it was inversely correlated with eGFR. Higher concentrations of asprosin in the T2DM and T2DM + NP groups and its relationship with glucose and lipid metabolism and markers of renal function and inflammation suggested a possible role for this adipokine in the pathogenesis of both T2DM and nephropathy.
Identifiants
pubmed: 34304366
doi: 10.1007/s11033-021-06551-2
pii: 10.1007/s11033-021-06551-2
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
FBN1 protein, human
0
Fibrillin-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5443-5450Subventions
Organisme : Shahid Beheshti University of Medical Sciences
ID : 98432
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE, Makaroff LE (2017) IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024
doi: 10.1016/j.diabres.2017.03.024
pubmed: 28437734
Montane J, Cadavez L, Novials A (2014) Stress and the inflammatory process: a major cause of pancreatic cell death in type 2 diabetes. Diabetes Metab Syndr Obes 7:25–34. https://doi.org/10.2147/DMSO.S37649
doi: 10.2147/DMSO.S37649
pubmed: 24520198
pmcid: 3917922
Poitout V, Amyot J, Semache M, Zarrouki B, Hagman D, Fontes G (2010) Glucolipotoxicity of the pancreatic beta cell. Biochim Biophys Acta 1801(3):289–298. https://doi.org/10.1016/j.bbalip.2009.08.006
doi: 10.1016/j.bbalip.2009.08.006
pubmed: 19715772
Zou W, Wang H (2009) Pathology of renal biopsy. Peking University Medical Press, Beijing
KDOQI (2007) KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney 49(2 Suppl 2):S12–154. https://doi.org/10.1053/j.ajkd.2006.12.005
Dronavalli S, Duka I, Bakris GL (2008) The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4(8):444–452. https://doi.org/10.1038/ncpendmet0894
doi: 10.1038/ncpendmet0894
pubmed: 18607402
Navarro-Gonzalez JF, Mora-Fernandez C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19(3):433–442. https://doi.org/10.1681/ASN.2007091048
doi: 10.1681/ASN.2007091048
pubmed: 18256353
Conte C, Fabbrini E, Kars M, Mittendorfer B, Patterson BW, Klein S (2012) Multiorgan insulin sensitivity in lean and obese subjects. Diabetes Care 35(6):1316–1321. https://doi.org/10.2337/dc11-1951
doi: 10.2337/dc11-1951
pubmed: 22474039
pmcid: 3357234
Andrade-Oliveira V, Câmara NO, Moraes-Vieira PM (2015) Adipokines as drug targets in diabetes and underlying disturbances. J Diabetes Res. https://doi.org/10.1155/2015/681612
doi: 10.1155/2015/681612
pubmed: 25918733
pmcid: 4397001
Ahima RS (2006) Adipose tissue as an endocrine organ. Obesity 14(S8):242S-249S
doi: 10.1038/oby.2006.317
Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444(7121):875–880. https://doi.org/10.1038/nature05487
doi: 10.1038/nature05487
pubmed: 17167476
Booth A, Magnuson A, Fouts J, Foster MT (2016) Adipose tissue: an endocrine organ playing a role in metabolic regulation. Horm Mol Biol Clin Investig 26(1):25–42. https://doi.org/10.1515/hmbci-2015-0073
doi: 10.1515/hmbci-2015-0073
pubmed: 26910750
Zhang L, Fu Y, Zhou N, Cheng X, Chen C (2017) Circulating neuregulin 4 concentrations in patients with newly diagnosed type 2 diabetes: a cross-sectional study. Endocrine 57(3):535–538. https://doi.org/10.1007/s12020-017-1324-3
doi: 10.1007/s12020-017-1324-3
pubmed: 28523627
Jia Y, Luo X, Ji Y, Xie J, Jiang H, Fu M, Li X (2017) Circulating CTRP9 levels are increased in patients with newly diagnosed type 2 diabetes and correlated with insulin resistance. Diabetes Res Clin Pract 131:116–123. https://doi.org/10.1016/j.diabres.2017.07.003
doi: 10.1016/j.diabres.2017.07.003
pubmed: 28743061
Clark M, Hoenig M (2016) Metabolic effects of obesity and its interaction with endocrine diseases. Vet Clin North Am Small Anim Pract 46(5):797–815. https://doi.org/10.1016/j.cvsm.2016.04.004
doi: 10.1016/j.cvsm.2016.04.004
pubmed: 27297495
Tesauro M, Canale MP, Rodia G, Di Daniele N, Lauro D, Scuteri A, Cardillo C (2011) Metabolic syndrome, chronic kidney, and cardiovascular diseases: role of adipokines. Cardiol Res Pract 2011:653182. https://doi.org/10.4061/2011/653182
doi: 10.4061/2011/653182
pubmed: 21403882
pmcid: 3051177
Fujita T, Ogihara N, Kamura Y, Satomura A, Fuke Y, Shimizu C, Wada Y, Matsumoto K (2012) Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol 49(2):111–117
doi: 10.1007/s00592-010-0178-4
Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B, Sarkar P, Rendon DA, Gaber MW, LeMaire SA, Coselli JS, Milewicz DM, Sutton VR, Butte NF, Moore DD, Chopra AR (2016) Asprosin, a fasting-induced glucogenic protein hormone. Cell 165(3):566–579. https://doi.org/10.1016/j.cell.2016.02.063
doi: 10.1016/j.cell.2016.02.063
pubmed: 27087445
pmcid: 4852710
Zhang L, Chen C, Zhou N, Fu Y, Cheng X (2019) Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta 489:183–188. https://doi.org/10.1016/j.cca.2017.10.034
doi: 10.1016/j.cca.2017.10.034
pubmed: 29104036
Lee T, Yun S, Jeong JH, Jung TW (2019) Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol 486:96–104
doi: 10.1016/j.mce.2019.03.001
Jung TW, Kim HC, Kim HU, Park T, Park J, Kim U, Kim MK, Jeong JH (2019) Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle. J Cell Physiol 234(11):20888–20899
doi: 10.1002/jcp.28694
Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, Saha PK, Lee ME, Phillips KJ, Jain M (2017) Asprosin is a centrally acting orexigenic hormone. Nat Med 23(12):1444
doi: 10.1038/nm.4432
Sauvanet JP (2003) Congress of the International Diabetes Federation (IDF-Paris 2003). Presse Med 32(39):1864–1868
pubmed: 14713884
O’neill S, O’driscoll L (2015) Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev 16(1):1–12
doi: 10.1111/obr.12229
Titchenell PM, Lazar MA, Birnbaum MJ (2017) Unraveling the regulation of hepatic metabolism by insulin. Trends Endocrinol Metab 28(7):497–505. https://doi.org/10.1016/j.tem.2017.03.003
doi: 10.1016/j.tem.2017.03.003
pubmed: 28416361
pmcid: 5477655
Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI (1992) Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest 90(4):1323–1327. https://doi.org/10.1172/JCI115997
doi: 10.1172/JCI115997
pubmed: 1401068
pmcid: 443176
Czech MP (2017) Insulin action and resistance in obesity and type 2 diabetes. Nat Med 23(7):804–814. https://doi.org/10.1038/nm.4350
doi: 10.1038/nm.4350
pubmed: 28697184
pmcid: 6048953
Duran-Salgado MB, Rubio-Guerra AF (2014) Diabetic nephropathy and inflammation. World J Diabetes 5(3):393–398. https://doi.org/10.4239/wjd.v5.i3.393
doi: 10.4239/wjd.v5.i3.393
pubmed: 24936261
pmcid: 4058744